Atorvastatin evokes a serotonergic system-dependent antidepressant-like effect in mice

作者：Ludka Fabiana K; Constantino Leandra Celso; Kuminek Gislaine; Binder Luisa Bandeira; Zomkowski Andrea D E; Cunha Mauricio P; Dal Cim Tharine; Rodrigues Ana Lucia S; Tasca Carla I^*

来源：Pharmacology Biochemistry and Behavior, 2014, 122: 253-260.

DOI：10.1016/j.pbb.2014.04.005

• Statin
• Atorvastatin
• Antidepressant-like effect
• Tail suspension test
• Serotonergic system
• Serotonin

Atorvastatin is a statin largely used in the treatment of hypercholesterolemia and recently revealed as a neuroprotective agent. The antidepressant-like effect of acute atorvastatin treatment in mice has been previously demonstrated by our laboratory. The purpose of this study was to explore the contribution of the serotonergic system in the antidepressant-like effect of atorvastatin in mice. Data demonstrate that the serotonin (5-HT) depleting agent p-chlorophenylalanine methyl ester (PCPA, 100 mg/kg, i.p.) completely abolished atorvastatin (0.1 mg/kg, p.o.) antidepressant-like effect. Besides atorvastatin, fluoxetine (10 mg/kg, p.o.), a serotonin selective reuptake inhibitor (SSRI) was able to exert an antidepressant-like effect, but any of them changed 5-HT content in the hippocampus or frontal cortex. The 5H-T1A (WAY100635, 0.1 mg/kg, s.c) or the 5-HT2A/2C (ketanserin, 5 mg/kg, s.c.) receptor antagonists prevented atorvastatin antidepressant-like effect. In addition, a combinatory antidepressant-like effect was observed when mice received the co-administration of sub-effective doses of atorvastatin (0.01 mg/kg, p.o.) and the SSRI fluoxetine (5 mg/kg, p.o.), paroxetine (0.1 mg/kg, p.o.) or sertraline (1 mg/kg, p.o.). Taken together, these results indicate that the antidepressant-like effect of atorvastatin depends on the serotonergic system modulation.

• 出版日期2014-7